Tracie Saunders

644 total citations
13 papers, 153 citations indexed

About

Tracie Saunders is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tracie Saunders has authored 13 papers receiving a total of 153 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 4 papers in Molecular Biology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tracie Saunders's work include Cancer Treatment and Pharmacology (4 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Ovarian cancer diagnosis and treatment (2 papers). Tracie Saunders is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Ovarian cancer diagnosis and treatment (2 papers). Tracie Saunders collaborates with scholars based in United States and United Kingdom. Tracie Saunders's co-authors include Margarette Bryan, Robert Wieder, Lillian Pliner, Lawrence E. Harrison, Anna C. Pavlick, Dianne Pulte, Ann W. Silk, Andrew Zloza, Michael P. Kane and Bruce W. Hollis and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgical Oncology and Frontiers in Oncology.

In The Last Decade

Tracie Saunders

13 papers receiving 149 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tracie Saunders United States	6	77	37	32	23	21	13	153
Yves–Jean Bignon France	7	91 1.2×	40 1.1×	33 1.0×	9 0.4×	13 0.6×	9	169
Peiyuan Tang China	6	86 1.1×	72 1.9×	16 0.5×	8 0.3×	19 0.9×	7	223
Julio Velasco Spain	7	89 1.2×	32 0.9×	50 1.6×	6 0.3×	9 0.4×	13	198
Margaret Redpath Canada	8	83 1.1×	70 1.9×	63 2.0×	21 0.9×	20 1.0×	17	257
Michel Vulfovich United States	6	54 0.7×	59 1.6×	10 0.3×	7 0.3×	11 0.5×	9	145
Sam Lee Canada	5	107 1.4×	15 0.4×	27 0.8×	51 2.2×	10 0.5×	5	217
Junyu He China	9	94 1.2×	30 0.8×	30 0.9×	6 0.3×	68 3.2×	25	212
Tamsin R.M. Lannagan United Kingdom	7	75 1.0×	58 1.6×	9 0.3×	12 0.5×	32 1.5×	20	186
Hua Lou China	8	67 0.9×	27 0.7×	13 0.4×	52 2.3×	32 1.5×	15	241
Ana C.F. Bolhaqueiro Netherlands	3	29 0.4×	40 1.1×	45 1.4×	14 0.6×	3 0.1×	3	104

Countries citing papers authored by Tracie Saunders

Since Specialization

Citations

This map shows the geographic impact of Tracie Saunders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tracie Saunders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tracie Saunders more than expected).

Fields of papers citing papers by Tracie Saunders

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tracie Saunders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tracie Saunders. The network helps show where Tracie Saunders may publish in the future.

Co-authorship network of co-authors of Tracie Saunders

This figure shows the co-authorship network connecting the top 25 collaborators of Tracie Saunders. A scholar is included among the top collaborators of Tracie Saunders based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tracie Saunders. Tracie Saunders is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Silk, Ann W., Brendan D. Curti, Jennifer L. Bryan, et al.. (2023). A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma. Frontiers in Oncology. 13. 1108341–1108341. 8 indexed citations

Höchster, Howard S., Hao Liu, Lyudmyla Berim, et al.. (2023). Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer.. Journal of Clinical Oncology. 41(4_suppl). 144–144. 1 indexed citations

Silk, Ann W., Biren Saraiya, Roman Groisberg, et al.. (2022). A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors. European journal of medical research. 27(1). 107–107. 13 indexed citations

Fernández, Cristina R., et al.. (2019). Human immunodeficiency disease in new diagnoses of head and neck squamous cell cancer: are we testing?. The Journal of Laryngology & Otology. 133(12). 1038–1040. 1 indexed citations

Stein, Mark N., Jyoti Malhotra, Usha Malhotra, et al.. (2018). Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.. Journal of Clinical Oncology. 36(15_suppl). 2595–2595. 1 indexed citations

Stein, Mark N., Nancy Chan, Ann W. Silk, et al.. (2017). Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients.. Journal of Clinical Oncology. 35(15_suppl). 2586–2586. 1 indexed citations

Rodríguez-Rodríguez, Lorna, Janice M. Mehnert, Ann W. Silk, et al.. (2017). Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC).. Journal of Clinical Oncology. 35(15_suppl). 5592–5592. 2 indexed citations

Stein, Mark N., Nancy Chan, Ann W. Silk, et al.. (2016). First-in-human trial of ONC201 in patients with refractory solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 2514–2514. 2 indexed citations

Wieder, Robert, Randall Teal, Tracie Saunders, & Bryan J. Weiner. (2013). Establishing a Minority-Based Community Clinical Oncology Program: The University of Medicine and Dentistry of New Jersey, New Jersey Medical School–University Hospital Cancer Center Experience. Journal of Oncology Practice. 9(2). e48–e54. 3 indexed citations

10.

Bryan, Margarette, Dianne Pulte, Lillian Pliner, et al.. (2010). A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer. Investigational New Drugs. 29(6). 1482–1487. 58 indexed citations

11.

Harrison, Lawrence E., et al.. (2007). Phase I Trial of Pegylated Liposomal Doxorubicin with Hyperthermic Intraperitoneal Chemotherapy in Patients Undergoing Cytoreduction for Advanced Intra-abdominal Malignancy. Annals of Surgical Oncology. 15(5). 1407–1413. 41 indexed citations

12.

Wieder, Robert, Steven Novick, Bruce W. Hollis, et al.. (2003). Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. Investigational New Drugs. 21(4). 445–452. 15 indexed citations

13.

Wieder, Robert, Anna C. Pavlick, Margarette Bryan, et al.. (2002). Phase I/II Trial of Accutane as a Potentiator of Carboplatin and Paclitaxel in Squamous Cell Carcinomas. American Journal of Clinical Oncology. 25(5). 447–450. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact